Search hospitals > Ontario > LONDON
London Regional Cancer Program
Claim this profileLONDON, Ontario N6A 4L6
Global Leader in Prostate Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Pancreatic Cancer
Conducts research for Cancer
412 reported clinical trials
22 medical researchers
Summary
London Regional Cancer Program is a medical facility located in LONDON, Ontario. This center is recognized for care of Prostate Cancer, Breast Cancer, Lung Cancer, Pancreatic Cancer, Cancer and other specialties. London Regional Cancer Program is involved with conducting 412 clinical trials across 297 conditions. There are 22 research doctors associated with this hospital, such as David Palma, MD, Lucas Mendez, MD, Louise Moist, and Francisco E. Perera.Area of expertise
1Prostate Cancer
Global LeaderStage IV
Stage III
Stage I
2Breast Cancer
Global LeaderStage IV
ER positive
HER2 negative
Top PIs
David Palma, MDLondon Regional Cancer Program of the Lawson Health Research Institute7 years of reported clinical research
Studies Cancer
Studies Pancreatic Cancer
12 reported clinical trials
18 drugs studied
Lucas Mendez, MDLondon Regional Cancer Program2 years of reported clinical research
Studies Prostate Cancer
Studies Endometrial Cancer
7 reported clinical trials
14 drugs studied
Louise MoistLondon Health Sciences Centre1 year of reported clinical research
Studies Chronic Kidney Disease
Studies Obesity
3 reported clinical trials
5 drugs studied
Francisco E. PereraLondon Regional Cancer Program3 years of reported clinical research
Studies Breast Cancer
Studies Ductal Carcinoma In Situ
3 reported clinical trials
4 drugs studied
Clinical Trials running at London Regional Cancer Program
Breast Cancer
Bladder Cancer
Prostate Cancer
Head and Neck Cancers
Melanoma
Brain Tumor
Cancer
Squamous Cell Carcinoma
Lung Cancer
Breast cancer
Imlunestrant
for Early Breast Cancer
This trial is testing a new medication called imlunestrant to see if it works better than standard hormone treatments for certain breast cancer patients. The study focuses on patients with early-stage breast cancer that is estrogen receptor positive and HER2 negative, who have already been on hormone therapy for a period of time and are at high risk of their cancer returning. Imlunestrant works by blocking estrogen from helping cancer cells grow.
Recruiting2 awards Phase 36 criteria
Pembrolizumab
for Triple-Negative Breast Cancer
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria
Chemotherapy + Hormone Therapy
for Breast Cancer
This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at London Regional Cancer Program?
London Regional Cancer Program is a medical facility located in LONDON, Ontario. This center is recognized for care of Prostate Cancer, Breast Cancer, Lung Cancer, Pancreatic Cancer, Cancer and other specialties. London Regional Cancer Program is involved with conducting 412 clinical trials across 297 conditions. There are 22 research doctors associated with this hospital, such as David Palma, MD, Lucas Mendez, MD, Louise Moist, and Francisco E. Perera.
Where is London Regional Cancer Program located?
The London Regional Cancer Program hospital is situated at 800 Commissioners Rd E, London, Ontario, Canada. For parking, visitors are advised to use lots P1 and P2 across from the main entrance on Level 2. Handicapped parking is available in lot P2.
Who should I call to ask about financial aid or insurance network?
For financial assistance related to cancer treatment, CancerCare's Hopeline at 800-813-4673 offers support for transportation, home care, child care, pet assistance, and wellness programs. The London Regional Cancer Program provides two patient assistance funds: the Massel-Cruickshank Breast Cancer Patient Assistance Fund and the Gene Goodreau Patient Assistance Fund, for emergency, short-term financial support. Additional resources and information can be found by contacting the London Regional Cancer Program at 519.685.8742.
What insurance does London Regional Cancer Program accept?
The London Regional Cancer Program (LRCP) at London Health Sciences Centre (LHSC) accepts insurance plans for cancer care services in Ontario, Canada, including the Ontario Health Insurance Plan (OHIP). OHIP covers most services provided by the LRCP, including radiation therapy, chemotherapy, and supportive care. For details on the acceptance of specific private insurance plans, please contact the LRCP directly.
What awards or recognition has London Regional Cancer Program received?
The London Regional Cancer Program (LRCP) at London Health Sciences Centre is renowned for its exceptional research and care, highlighted by Dr. David Palma's Canadian Cancer Society Award for Excellence. It houses the Cancer Clinical Research Unit (CCRU), facilitating and supporting clinical and translational research. Annually, the CCRU recruits 250-400 patients for 50 to 70 active trials, emphasizing its commitment to advancing cancer treatment.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.